Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy : pain relief and neuroprotection share a PPAR-alpha-mediated mechanism

Peer reviewedPublisher PD

(+/-)-Gelliusines A and B, two diastereomeric brominated tris-indole alkaloids from a deep water New Caledonian marine sponge (Gellius or Orina sp.)

Two new diastereomeric brominated tris-indole alkaloids occurring as enantiomeric pairs, (±)-gelliusine A (I) and its isomer (±)-gelliusine B, have been isolated from a deep water New Caledonian sponge (Gellius or Orina sp.), whose crude ext. exhibited cytotoxicity against KB cells. Their structures were elucidated by spectroscopic methods including one- and two-dimensional NMR spectroscopy. The major compd., I, which showed very weak cytotoxicity, proved to be active at the serotonin receptor

Experimental research activity on additive manufacturing of microwave passive waveguide components

All metal passive waveguide components are key building-blocks of several RF systems used for telecommunications, navigation, imaging, radio-astronomy, and cosmology. The accurate manufacture of these devices in Additive Manufacturing (AM) technologies can open the way to a high integration level of microwave functionalities with a significant cost and mass reduction. In the paper, after an introduction on the most common AM technologies with particular detail on selective laser melting (SLM) and stereo-lithography apparatus (SLA) processes, the results on the on-going research activity are discussed. Measured performances are reported for AM prototypes of Ku/K/Ka-band rectangular and circular waveguide lines, microwave filters and a smooth wall horn

Additive Manufacturing Technology for High Performances Feed Horn

In this work the design and manufacturing through selective laser melting technology of single-band dual circular feed-system operating in Ka-band is reported. In the feed design an AM oriented architecture has been employed. The measured performances confirms the good manufacturing of the system that satisfies very stringent requirements in terms of polarization purity

Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis

Previous studies have reported an involvement of neuroactive steroids as neuroprotective and anti-inflammatory agents in neurological disorders such as multiple sclerosis (MS); an analysis of their profile during a specific clinical phase of MS is largely unknown. The pregnenolone (PREG), dehydroepiandrosterone (DHEA), and allopregnanolone (ALLO) profile was evaluated in cerebrospinal fluid (CSF) in relapsing-remitting multiple sclerosis (RR-MS) patients as well as those in patients affected by non-inflammatory neurological (control group I) and without neurological disorders (control group II). An increase of PREG and DHEA values was shown in CSF of male and female RR-MS patients compared to those observed in both control groups. The ALLO values were significantly lower in female RR-MS patients than those found in male RR-MS patients and in female without neurological disorder. During the clinical relapse, we observed female RR-MS patients showing significantly increased PREG values compared to female RR-MS patients in stable phase, while their ALLO values showed a significant decrease compared to male RR-MS patients of the same group. Male RR-MS patients with gadolinium-enhanced lesions showed PREG and DHEA values higher than those found in female RR-MS patients with gadolinium-enhanced lesions. Similary, male RR-MS patients with gadolinium-enhanced lesions showed PREG and DHEA values higher than male without gadolinium-enhanced lesions. Female RR-MS patients with gadolinium-enhanced lesions showed DHEA values higher than those found in female RR-MS patients with gadolinium-enhanced lesions. Male and female RR-MS patients with gadolinium-enhanced lesions showed ALLO values higher than those found in respective gender groups without gadolinium-enhanced lesions. ALLO values were lower in male than in female RR-MS patients without gadolinium-enhanced lesions. Considering the pharmacological properties of neuroactive steroids and the observation that neurological disorders influence their concentrations, these endogenous compounds may have an important role as prognostic factors of the disease and used as markers of MS activity such as relapses

Breast milk butyrate as protective factor against food allergy

Conflicting evidences suggest a role for breast milk as pro- tective factor against food allergy. The major short chain fatty acids, butyrate produced by gut microbiota exerts positive effect on immune system. We aimed to see whether butyrate concen- tration in human milk is able to prevent food allergy in an animal model of cow milk allergy. Mature breast milk butyrate concentration from 40 healthy women (aged 21–42 yrs) was assessed by gas chromatography. 4- Week-old female C3H/HeOuJ mice were sensitized by oral route with -lactoglobulin (BLG, 20 mg) plus cholera toxin (CT, 10 g) as an adjuvant in the presence or absence of butyrate. Acute aller- gic skin response,anaphylactic symptom score, body temperature, intestinal permeability, anti-BLG IgE, IL-4 and IL-10 production were assessed soon after oral challenge. Mean butyrate concen- tration in breast milk was 0.75 mM (SD ± 0.15). Based on this concentration a daily dose of 30 mg/kg body weight was calculated. The same butyrate concentration was able to significantly prevent acute allergic skin response, anaphylactic symptom score, body temperature decrease, intestinal permeability increase, anti-BLG IgE, IL-4 and IL-10 production in CMA animal model (p < .05). Our data suggest a pivotal role for butyrate as an effective human milk component in food allergy prevention

Therapeutic Effects of Butyrate on Pediatric Obesity: A Randomized Clinical Trial

Importance: The pediatric obesity disease burden imposes the necessity of new effective strategies. Objective: To determine whether oral butyrate supplementation as an adjunct to standard care is effective in the treatment of pediatric obesity. Design, Setting, and Participants: A randomized, quadruple-blind, placebo-controlled trial was performed from November 1, 2020, to December 31, 2021, at the Tertiary Center for Pediatric Nutrition, Department of Translational Medical Science, University of Naples Federico II, Naples, Italy. Participants included children aged 5 to 17 years with body mass index (BMI) greater than the 95th percentile. Interventions: Standard care for pediatric obesity supplemented with oral sodium butyrate, 20 mg/kg body weight per day, or placebo for 6 months was administered. Main Outcomes and Measures: The main outcome was the decrease of at least 0.25 BMI SD scores at 6 months. The secondary outcomes were changes in waist circumference; fasting glucose, insulin, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, ghrelin, microRNA-221, and interleukin-6 levels; homeostatic model assessment of insulin resistance (HOMA-IR); dietary and lifestyle habits; and gut microbiome structure. Intention-to-treat analysis was conducted. Results: Fifty-four children with obesity (31 girls [57%], mean [SD] age, 11 [2.91] years) were randomized into the butyrate and placebo groups; 4 were lost to follow-up after receiving the intervention in the butyrate group and 2 in the placebo group. At intention-to-treat analysis (n = 54), children treated with butyrate had a higher rate of BMI decrease greater than or equal to 0.25 SD scores at 6 months (96% vs 56%, absolute benefit increase, 40%; 95% CI, 21% to 61%; P &lt; .01). At per-protocol analysis (n = 48), the butyrate group showed the following changes as compared with the placebo group: waist circumference, -5.07 cm (95% CI, -7.68 to -2.46 cm; P &lt; .001); insulin level, -5.41 μU/mL (95% CI, -10.49 to -0.34 μU/mL; P = .03); HOMA-IR, -1.14 (95% CI, -2.13 to -0.15; P = .02); ghrelin level, -47.89 μg/mL (95% CI, -91.80 to -3.98 μg/mL; P &lt; .001); microRNA221 relative expression, -2.17 (95% CI, -3.35 to -0.99; P &lt; .001); and IL-6 level, -4.81 pg/mL (95% CI, -7.74 to -1.88 pg/mL; P &lt; .001). Similar patterns of adherence to standard care were observed in the 2 groups. Baseline gut microbiome signatures predictable of the therapeutic response were identified. Adverse effects included transient mild nausea and headache reported by 2 patients during the first month of butyrate intervention. Conclusions and Relevance: Oral butyrate supplementation may be effective in the treatment of pediatric obesity. Trial Registration: ClinicalTrials.gov Identifier: NCT04620057